CORE
🇺🇦
make metadata, not war
Services
Services overview
Explore all CORE services
Access to raw data
API
Dataset
FastSync
Content discovery
Recommender
Discovery
OAI identifiers
OAI Resolver
Managing content
Dashboard
Bespoke contracts
Consultancy services
Support us
Support us
Membership
Sponsorship
Community governance
Advisory Board
Board of supporters
Research network
About
About us
Our mission
Team
Blog
FAQs
Contact us
In vitro and ex vivo antibacterial activity of levofloxacin against Pasteurella multocida and Escherichia coli isolated from rabbits (Oryctolagus cuniculus) – A preliminary study
Authors
Dace Bandere
Santa Purvina
Andrejs Sitovs
Ingus Skadins
Publication date
1 September 2023
Publisher
Doi
Cite
Abstract
Funding Information: This study was funded from the Riga Stradins University doctoral grant. Funding Information: The authors sincerely thank Dr. Aneliya Milanova (Trakia University, Bulgaria) and Dr. Cristina Vercelli (University of Turin, Italy) for their scientific advice and help. Publisher Copyright: © 2023 The Authors. Journal of Veterinary Pharmacology and Therapeutics published by John Wiley & Sons Ltd.Levofloxacin veterinary formulations are available in Argentina, China and India for the use in dogs, cattle, pig and sheep, but not currently in the rabbit. Only the extra-label use in rabbits is possible. Levofloxacin is not labelled for veterinary use in the EU or the USA. The activity of levofloxacin against rabbit pathogens Pasteurella multocida (P. multocida) and Escherichia coli (E. coli) was evaluated. Minimum inhibitory concentration (MIC) and minimal bactericidal concentration (MBC) were determined in broth and serum for 10 P. multocida isolates and 5 E. coli isolates from rabbits. One isolate of each bacterial species was used for the time-killing curve study in vitro and ex vivo. In vitro AUC24/MIC ratios were used for building the inhibitory pharmacodynamic Imax model. The P. multocida MIC were 0.008–0.5 μg/mL, MBC – 0.015–0.5 μg/mL. Escherichia coli MIC was 0.008–0.03 μg/mL and MBC – 0.03–0.25 μg/mL. Bacterial counts were reduced to the limit of detection after 24 h with levofloxacin concentrations of 2 MIC and higher. All serum samples from rabbits treated with levofloxacin eliminated the bacteria within 24 h. AUC24/MIC ratios for bacteriostatic, bactericidal and bacterial elimination effects for P. multocida and E. coli isolates were 21, 29 and 75 h and 27, 32 and 60 h, respectively. Proposed daily doses against P. multocida (MIC = 0.015 μg/mL) and E. coli (MIC = 0.03 μg/mL) isolates were calculated as ≤0.91 and ≤1.43 mg/kg, respectively. Fluoroquinolones are categorized by WHO as ‘highest priority critically important antimicrobials’. Considering the increasing importance of antimicrobial stewardship, antimicrobials from a lower importance category that are active against the isolate of interest should be used in preference to fluoroquinolones. Fluoroquinolone use in veterinary medicine should be based on antimicrobial susceptibility testing in order to mitigate the risk to public health and prevent the spread of bacterial resistance.Peer reviewe
Similar works
Full text
Open in the Core reader
Download PDF
Available Versions
Riga Stradins university
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:dspace.rsu.lv:123456789/14...
Last time updated on 25/10/2023